Delving into the Latest Updates on Signablok, Inc. with Synapse

概览

疾病领域	数量

神经系统疾病	3
内分泌与代谢疾病	2
感染	1
肿瘤	1

排名前五的药物类型	数量

重组多肽	6
小分子化药	1
化学药	1

排名前五的靶点	数量

TREM1(髓系细胞表达的触发受体-1)	7
TREM1 x TREM2	1

关联

8

项与 Signablok, Inc. 相关的药物

UHS-GBCA

靶点

TREM1

作用机制

TREM1抑制剂

在研机构

Signablok, Inc.

原研机构

Signablok, Inc.

在研适应症-

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Stroke(SignaBlok)

靶点

TREM1

作用机制

TREM1抑制剂

在研机构

Signablok, Inc.

原研机构

Signablok, Inc.

在研适应症

脑卒中

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Spinal Cord Injury(SignaBlok)

靶点

TREM1

作用机制

TREM1抑制剂

在研机构

Signablok, Inc.

原研机构

Signablok, Inc.

在研适应症

脊髓损伤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Signablok, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Signablok, Inc. 相关的专利（医药）

登录后查看更多信息

25

项与 Signablok, Inc. 相关的文献（医药）

2022-04-01·Biochimie3区 · 生物学

SARS-CoV-2 may affect the immune response via direct inhibition of T cell receptor: Mechanistic hypothesis and rationale

3区 · 生物学

Article

作者: Sigalov, Alexander B

During co-evolution with their hosts, many viruses have evolved a membrane fusion mechanism to facilitate host cell entry. Examples are human immunodeficiency virus type 1 (HIV-1) and severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV-1 and SARS-CoV-2). These viruses can also infect immune cells (e.g., T cells), providing one of the possible mechanisms for the T cell lymphopenia observed in patients with these infections. Previously, we hypothesized and confirmed in vivo that like HIV-1, SARS-CoV-1 can use its fusion domain not only to enter the T cell but also to directly inhibit T cell receptor signaling. Here, based on the analysis of available structural and clinical data, we hypothesize that SARS-CoV-2 may use a similar "disarm the alarm" strategy to suppress immune responses. We also discuss the implications of this hypothesis for better understanding coronavirus disease 2019 (COVID-19) pathology, developing effective COVID-19 vaccines and improving clinical outcomes for COVID-19 patients.

2021-09-16·Infection and Immunity2区 · 医学

Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) Contributes to Bordetella pertussis Inflammatory Pathology

2区 · 医学

Article

作者: Ardanuy, Jeremy ; Gallop, Danisha ; Scanlon, Karen M. ; Skerry, Ciaran ; Sigalov, Alexander B. ; Carbonetti, Nicholas H.

Whooping cough (pertussis) is a severe pulmonary infectious disease caused by the bacteria Bordetella pertussis . Pertussis infects an estimated 24 million people annually, resulting in >150,000 deaths.

2020-08-01·Drug Discovery Today2区 · 医学

SCHOOL of nature: ligand-independent immunomodulatory peptides

2区 · 医学

Article

作者: Sigalov, Alexander B

Groundbreaking studies in protein biophysics have identified the mechanisms of transmembrane signaling at the level of druggable protein-protein interactions (PPIs). This resulted in the development of the signaling chain homooligomerization (SCHOOL) strategy to modulate cell responses using receptor-specific peptides. Inspired by nature, these short peptides use ligand-independent mechanisms of receptor inhibition and demonstrate potent efficacy in vitro and in vivo. The SCHOOL strategy is especially important when receptor ligands are unknown. An example is the triggering receptor expressed on myeloid cells-1 (TREM-1) receptor, an emerging therapeutic target involved in the pathogenesis of most inflammatory diseases. Here, I discuss advances in the field with a focus on TREM-1 inhibitory SCHOOL peptides that offer new hope for a 'magic bullet' cure for cancer, arthritis, sepsis, retinopathy, and other medical challenges.

100 项与 Signablok, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Signablok, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月27日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

8

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Neurodegenerative disorder(SignaBlok) ( TREM1 x TREM2 )	阿尔茨海默症更多	临床前
Retinopathy(SignaBlok) ( TREM1 )	早产儿视网膜病变更多	临床前
Liver Diseases(SignaBlok) ( TREM1 )	代谢功能障碍相关的脂肪肝病更多	临床前
UHS-GBCA ( TREM1 )	-	临床前
TREM-1 inhibitor (SignaBlok) ( TREM1 )	新型冠状病毒感染更多	临床前